Most researchers searching for CJC-1295 in Avon soon discover that local retail options are all but absent from local stores. This global online supply model is actually an advantage for quality — top vendors differentiate through analytical documentation in ways no local retailer can match. What reliably differentiates top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for contamination assurance. This guide gives Avon researchers the framework to assess vendor quality rigorously and source high-purity CJC-1295 with confidence.
CJC-1295 Mechanisms Explained
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Avon researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
Evaluating CJC-1295 vendors begins with the COA: access the batch-specific certificate before placing an order, not after. The HPLC purity trace is the most important document in the COA: it should show a dominant main peak representing CJC-1295, with small or absent impurity peaks representing impurities — purity should be stated as ≥98%. Signs of a credible vendor beyond COA quality: established track record of at least two years, knowledgeable support capable of explaining COA data, and temperature-appropriate packaging with desiccant. Price is an unreliable primary filter for CJC-1295 quality — research-grade synthesis and testing has genuine production costs that cannot be cut without consequences, so the lowest-priced options almost always involve trade-offs.
Order CJC-1295 — ships to Avon
COA-verified · International tracking · Research grade
CJC-1295 operates outside approved pharmaceutical regulation — researchers should understand that the risk characterisation for this compound is based on academic studies rather than pharmaceutical approval data. Reconstitute CJC-1295 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg vial with 2mL bac water yields 2.5mg/mL — providing 25mcg per unit measured on a 100-unit syringe. Bacterial endotoxin contamination is the primary safety concern specific to research peptides — verify endotoxin testing is included in the batch-specific COA before any injectable research application. Protocol documentation — recording exactly what was used, when, and how — is a fundamental research principle that allows any unexpected observations to be properly contextualised.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
